GlassScriptPhysician profile
Marie Moore
NPI 1124242375
$21,356.36
in general payments reported to CMS, 2019-2025
13 companies · $29.95 in 2025
The $29.95 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,229 · 2022: $6,853 · 2023: $9,071 · 2024: $4,174 · 2025: $29.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,954 · Food and Beverage: $1,918 · Travel and Lodging: $1,050 · Grant: $750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $550 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,954.00 |
| Food and Beverage | $1,918.24 |
| Travel and Lodging | $1,049.91 |
| Grant | $750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $550.00 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $7,292.71 | 2021-2023 | |
| Emd Serono, INC. | $6,282.68 | 2021-2024 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $2,595.08 | 2022-2023 | |
| Celgene Corporation | $1,726.39 | 2022-2023 | Zeposia |
| Mylan Specialty L.P. | $1,106.15 | 2023 | |
| Tg Therapeutics, INC. | $1,027.23 | 2021-2024 | |
| Cycle Pharmaceuticals INC | $550.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $355.39 | 2022-2023 | Kesimpta |
| Biogen, INC. | $200.72 | 2022-2023 | Tysabri, Vumerity |
| Lundbeck LLC | $125.00 | 2022 | |
| Genentech, INC. | $52.43 | 2023-2024 | Ocrevus |
| Janssen Scientific Affairs, LLC | $29.95 | 2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.